July kicks off the latter half of 2025, and the first six months of this year have been eventful, to say the least. Yet, the ...

Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.

In December, Novo Nordisk reported that CagriSema was able to muster a 22.7% weight loss at 68 weeks in REDEFINE 1, which also fell short of its hoped-for reduction of 25%.

CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type ...

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

The market for weight management medicines has been the hottest therapeutic area in the past two years. The pharmaceutical ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

Novo Nordisk shares fell due to a supply issue in the US, disappointing trial results for its new weight loss drug CagriSema, and heightened competition. The trust declared an interim dividend of 1.4p ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...